千红制药
(002550)
| 流通市值：60.08亿 | | | 总市值：80.63亿 |
| 流通股本：9.54亿 | | | 总股本：12.80亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 758,365,706.37 | 358,078,398.61 | 1,571,276,512.22 | 1,215,015,041.44 |
| 营业收入 | 758,365,706.37 | 358,078,398.61 | 1,571,276,512.22 | 1,215,015,041.44 |
| 二、营业总成本 | 610,318,487.25 | 265,121,901.26 | 1,260,212,744.09 | 918,885,764.41 |
| 营业成本 | 354,480,473.8 | 139,363,947.63 | 654,347,578.18 | 513,791,258.84 |
| 税金及附加 | 10,333,971.59 | 5,201,307.45 | 21,938,558.15 | 16,772,275.46 |
| 销售费用 | 117,281,156.05 | 57,310,050.47 | 317,819,774.94 | 223,851,795.96 |
| 管理费用 | 72,541,727.82 | 34,733,246.43 | 150,635,247.63 | 94,809,026.01 |
| 研发费用 | 43,211,217.62 | 20,494,634.72 | 110,662,137.29 | 69,864,138.78 |
| 财务费用 | 12,469,940.37 | 8,018,714.56 | 4,809,447.9 | -202,730.64 |
| 其中:利息费用 | - | - | 459,106.24 | 436,237.36 |
| 其中:利息收入 | 5,865,621.94 | 2,373,677.83 | 9,978,504.68 | 7,385,362.8 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,552,124.06 | 3,325,818.6 | 6,548,550.29 | 3,738,861.33 |
| 加:投资收益 | 4,351,641.43 | 706,539.12 | 11,592,371.35 | 9,500,453.35 |
| 资产处置收益 | - | - | 14,356.7 | 18,560.95 |
| 资产减值损失(新) | - | - | -5,295,397.52 | - |
| 信用减值损失(新) | -46,172.61 | -216,068.94 | 115,070,517.36 | 115,198,431.68 |
| 其他收益 | 8,024,742.24 | 5,958,090.16 | 16,636,974.8 | 13,559,731.58 |
| 四、营业利润 | 167,929,554.24 | 102,730,876.29 | 455,631,141.11 | 438,145,315.92 |
| 加:营业外收入 | 150,020.42 | 86,378.11 | 12,380.6 | 19,945.46 |
| 减:营业外支出 | 746,396.16 | 17,265.66 | 5,461,575.85 | 366,575.32 |
| 五、利润总额 | 167,333,178.5 | 102,799,988.74 | 450,181,945.86 | 437,798,686.06 |
| 减:所得税费用 | 24,450,597.01 | 18,302,399.87 | 76,926,997.92 | 69,665,057.46 |
| 六、净利润 | 142,882,581.49 | 84,497,588.87 | 373,254,947.94 | 368,133,628.6 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 142,882,581.49 | 84,497,588.87 | 373,254,947.94 | 368,133,628.6 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 152,825,677.07 | 85,055,061.19 | 398,795,539.59 | 383,226,284.88 |
| 少数股东损益 | -9,943,095.58 | -557,472.32 | -25,540,591.65 | -15,092,656.28 |
| 扣除非经常损益后的净利润 | 142,140,512.4 | 77,407,361.14 | 283,349,240.75 | 271,049,454.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.07 | 0.32 | 0.31 |
| (二)稀释每股收益 | 0.12 | 0.07 | 0.32 | 0.31 |
| 八、其他综合收益 | -142,698.11 | -1,441,250.69 | 1,869,290.37 | 397,763.3 |
| 归属于母公司股东的其他综合收益 | -142,698.11 | -1,441,250.69 | 1,869,290.37 | 397,763.3 |
| 九、综合收益总额 | 142,739,883.38 | 83,056,338.18 | 375,124,238.31 | 368,531,391.9 |
| 归属于母公司股东的综合收益总额 | 152,682,978.96 | 83,613,810.5 | 400,664,829.96 | 383,624,048.18 |
| 归属于少数股东的综合收益总额 | -9,943,095.58 | -557,472.32 | -25,540,591.65 | -15,092,656.28 |
| 公告日期 | 2026-08-08 | 2026-04-24 | 2026-04-24 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |